As reported and read in Science Daily, researchers at the Northwestern University (USA), led by Prof. Evan Scott and Pro. Guillermo Ammer, have published a paper in the Nature Nanotechnology journal (pub. 17^th January 2022) research and findings that could offer new hope for the treatment of T1 diabetes.

As we know, those living with Type 1 (T1) diabetes have strict medication (including insulin) routines that must be followed every day by means of injection or other delivery devices.  This, of course, can have a profound effect on an individual’s wellbeing and lifestyle in many ways, some more than others.

There have been many attempts at transplantations that can help the body control sugar levels and insulin production through the transplantation of islets, pancreatic islets control insulin production in response to blood sugar levels, but this has not always been successful.

The team at Northwestern University have, according to their research findings, discovered a technique that may help to make this more effective.  Prof. Guillermo Ameer has previously been working on islet transplantation and encountered problems associated with systemic immunosuppression.

Along with Prof Evan Scott et al, the research conducted focuses on the nanocarriers that use the immunosuppressant ‘rapamycin’, which is then capable to target specific cells in the body without suppressing other immune responses.

There is, of course, much more to this research article that we would urge you to read to further your understanding, but Well Heeled likes to bring any news that could further the research into diabetes, and treatments therein, to help you to delve into this story further.

Article Ref. – https://www.nature.com/articles/s41565-021-01048-2